215 related articles for article (PubMed ID: 31239086)
1. Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder.
Herring AA; Schultz CW; Yang E; Greenwald MK
Am J Emerg Med; 2019 Dec; 37(12):2259-2262. PubMed ID: 31239086
[No Abstract] [Full Text] [Related]
2. Elective Naloxone-Induced Opioid Withdrawal for Rapid Initiation of Medication-Assisted Treatment of Opioid Use Disorder.
Phillips RH; Salzman M; Haroz R; Rafeq R; Mazzarelli AJ; Pelletier-Bui A
Ann Emerg Med; 2019 Sep; 74(3):430-432. PubMed ID: 30773411
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
4. Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.
Strain EC; Harrison JA; Bigelow GE
Clin Pharmacol Ther; 2011 Mar; 89(3):443-9. PubMed ID: 21270789
[TBL] [Abstract][Full Text] [Related]
5. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
Cottrill CB; Matson SC
Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
[No Abstract] [Full Text] [Related]
6. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
[No Abstract] [Full Text] [Related]
7. Peer navigation and take-home naloxone for opioid overdose emergency department patients: Preliminary patient outcomes.
Samuels EA; Bernstein SL; Marshall BDL; Krieger M; Baird J; Mello MJ
J Subst Abuse Treat; 2018 Nov; 94():29-34. PubMed ID: 30243414
[No Abstract] [Full Text] [Related]
8. Naloxone Dosing After Opioid Overdose in the Era of Illicitly Manufactured Fentanyl.
Carpenter J; Murray BP; Atti S; Moran TP; Yancey A; Morgan B
J Med Toxicol; 2020 Jan; 16(1):41-48. PubMed ID: 31471760
[TBL] [Abstract][Full Text] [Related]
9. An increase in per-patient naloxone requirements in an opioid epidemic.
Birmingham LE; Nielson JA
Am J Emerg Med; 2017 Dec; 35(12):1958-1959. PubMed ID: 28633907
[No Abstract] [Full Text] [Related]
10. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
[TBL] [Abstract][Full Text] [Related]
11. Building bridges to outpatient treatment services for post-overdose care via paramedic buprenorphine field initiation.
Belden C; Kopak A; Coules C; Friesen T; Hall J; Shukla S
J Subst Use Addict Treat; 2024 Jul; 162():209364. PubMed ID: 38626851
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
13. A 20-Year-Old Woman With Severe Opioid Toxicity.
Solomon R
J Emerg Nurs; 2018 Jan; 44(1):77-78. PubMed ID: 28427726
[No Abstract] [Full Text] [Related]
14. Naloxone--does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose.
Neale J; Strang J
Addiction; 2015 Oct; 110(10):1644-52. PubMed ID: 26119038
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
16. Comparing methods of naloxone administration: A narrative review.
Fellows SE; Coppola AJ; Gandhi MA
J Opioid Manag; 2017; 13(4):253-260. PubMed ID: 28953317
[TBL] [Abstract][Full Text] [Related]
17. Naloxone prescribing: room for finesse.
Gilham J; Lloyd G
Br J Hosp Med (Lond); 2019 Mar; 80(3):C46-C48. PubMed ID: 30860915
[No Abstract] [Full Text] [Related]
18. Intranasal Naloxone Administration.
Ortega R; Nozari A; Baker W; Surani S; Edwards M
N Engl J Med; 2021 Mar; 384(12):e44. PubMed ID: 33761209
[No Abstract] [Full Text] [Related]
19. Pulmonary Complications of Opioid Overdose Treated With Naloxone.
Farkas A; Lynch MJ; Westover R; Giles J; Siripong N; Nalatwad A; Pizon AF; Martin-Gill C
Ann Emerg Med; 2020 Jan; 75(1):39-48. PubMed ID: 31182316
[TBL] [Abstract][Full Text] [Related]
20. Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.
Yokell MA; Zaller ND; Green TC; McKenzie M; Rich JD
J Opioid Manag; 2012; 8(1):63-6. PubMed ID: 22479887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
